Science News
from research organizations

Engineered Human Fusion Protein Inhibits HIV-1 Replication

Date:
September 8, 2009
Source:
Journal of Clinical Investigation
Summary:
Fusion protein AoT5Cyp blocks HIV-1 infection in owl monkeys. The human genome encodes the equivalent of the 2 components of AoT5Cyp (TRIM5 and cyclophilin A), but humans unfortunately do not make the fusion protein. Researchers have now fused human cyclophilin A and TRIM5 and this protein inhibited HIV-1 replication in human macrophages, T cells and mice engrafted with human CD4+ T cells containing the protein. This protein may be an anti-HIV-1 gene therapy candidate.
Share:
       
Total shares:  
FULL STORY

In 2004, Jeremy Luban and colleagues from the University of Geneva, Switzerland, reported that New World owl monkeys (Aotus genus) make a fusion protein – AoT5Cyp – that potently blocks HIV-1 infection. The human genome encodes the equivalent of the 2 components of AoT5Cyp (i.e., TRIM5 and cyclophilin A), but humans unfortunately do not make the T5Cyp fusion protein.

In their new study in the Journal of Clinical Investigation, Luban et al. have engineered a human HIV-1 inhibitor modeled after AoT5Cyp, by fusing human cyclophilin A to human TRIM5 (hT5Cyp). The human fusion protein blocked HIV-1 infection of human macrophage and T cell lines, without disrupting normal cell function.

Mice engineered to lack B, T, and NK immune cells (to ensure that the animals do not reject grafts of human material) were then engrafted with human CD4+ T cells engineered to contain hT5Cyp. HIV-1 replication was potently inhibited in these animals.

The authors concluded that hT5Cyp is a robust inhibitor of HIV-1 replication and a promising anti–HIV-1 gene therapy candidate.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Luban et al. Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI39354

Cite This Page:

Journal of Clinical Investigation. "Engineered Human Fusion Protein Inhibits HIV-1 Replication." ScienceDaily. ScienceDaily, 8 September 2009. <www.sciencedaily.com/releases/2009/09/090908193430.htm>.
Journal of Clinical Investigation. (2009, September 8). Engineered Human Fusion Protein Inhibits HIV-1 Replication. ScienceDaily. Retrieved May 22, 2015 from www.sciencedaily.com/releases/2009/09/090908193430.htm
Journal of Clinical Investigation. "Engineered Human Fusion Protein Inhibits HIV-1 Replication." ScienceDaily. www.sciencedaily.com/releases/2009/09/090908193430.htm (accessed May 22, 2015).

Share This Page:


Health & Medicine News
May 22, 2015

Latest Headlines
updated 12:56 pm ET